The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Rivastigmine for dementia associated with Parkinson's disease.
Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. ⋯ In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.